Pfizer's Inhaled Insulin Linked To Lung Cancer
Posted on April 09, 2008 at 17:58 PM EDT
Pfizer Inc. (NYSE: PFE) reported that a handful of smokers testing its inhaled insulin drug treatment developed lung cancer. Shares of its partner Nektar Therapeutics (Nasdaq: NKTR) plummeted $1.80 to close at $5.39 while shares of rival Mannkind Corp. (Nasdaq: MNKD) skidded $3.50 to close at $2.35. Pfizer stock eased 11 cents to close at $20.89.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here